Profluent & Lilly Join Hands in 2.25 Billion USD Genetic Medicine Deal

Artificial intelligence-focused biotech company Profluent has partnered with pharmaceutical major Eli Lilly and Company in a genetic medicine deal worth up to $2.25 billion. The collaboration aims to develop advanced gene-editing therapies using AI-designed enzymes that could help treat complex diseases.

The partnership reflects the growing role of artificial intelligence in healthcare and drug discovery. Profluent will use its AI technology to design specialized proteins and enzymes that can make precise changes to DNA. These tools could support the development of new treatments for genetic disorders and other difficult-to-treat conditions.

Under the agreement, Profluent and Lilly will work together on several research programs focused on creating recombinases — enzymes capable of editing DNA at specific locations. Researchers believe these enzymes may offer more flexibility than existing gene-editing technology by enabling larger or more targeted DNA modifications.

Profluent is known for using advanced AI models to generate protein design technology that may perform better than naturally occurring biological systems. By combining this innovation with Lilly’s experience in drug development and commercialization, the companies hope to accelerate the creation of next-generation genetic medicines.

Also Read: India Powers Oxford Malaria Vaccine Pact for Global Rollout

Financially, the deal includes an upfront payment to Profluent, along with research funding and milestone-based payments linked to scientific progress, regulatory approvals, and commercial success. If products developed through the partnership reach the market, Profluent may also earn royalties from future sales. The total value of the agreement could rise to $2.25 billion depending on the success of the programs.

The collaboration also highlights Lilly’s continued investment in AI-powered biotechnology. The company has been expanding its partnerships with firms specializing in gene editing and AI-driven research to strengthen its pipeline of innovative treatments.

As pharmaceutical companies increasingly adopt AI tools to improve research efficiency, partnerships like this are becoming more common. Industry experts believe precision medicine, biotechnology innovation, and DNA editing research have the potential to shorten development timelines and help bring new therapies to patients faster.